Compare FVRR & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FVRR | GLSI |
|---|---|---|
| Founded | 2010 | 2006 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 372.4M | 327.2M |
| IPO Year | 2019 | 2020 |
| Metric | FVRR | GLSI |
|---|---|---|
| Price | $10.85 | $27.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | $18.43 | ★ $50.00 |
| AVG Volume (30 Days) | ★ 877.5K | 102.0K |
| Earning Date | 04-29-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.83 | N/A |
| P/E Ratio | $22.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.67 | $7.78 |
| 52 Week High | $34.13 | $34.10 |
| Indicator | FVRR | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 49.49 | 59.92 |
| Support Level | $9.97 | $20.86 |
| Resistance Level | $11.33 | $30.08 |
| Average True Range (ATR) | 0.52 | 1.69 |
| MACD | -0.06 | 0.46 |
| Stochastic Oscillator | 32.46 | 78.15 |
Fiverr International Ltd operates a online marketplace that enables sellers to offer digital services and buyers to purchase them The Company's platform features an extensive catalog of digital services that spans over hundreds of categories. Buyers can purchase digital services ranging from simple services such as logo design and blog post writing, to complex services such as video creation, website development and social media marketing. Also, the Company offers value-added services including subscription products, advertising solutions and financial tools designed to support marketplace users and enhance their business activities. The company generates maximum of its revenue from USA.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.